The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 15, Issue 4
Editorial
Intellectual property and biotechnology innovation: To protect or not protect? | |
Yali Friedman |
Commentary
The correlation between medical tourism and biotechnology | |
David G Vequist IV, Erika Valdez |
The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interview | |
William Bains |
Articles
Innovate America: The Technology Innovation Program at NIST | |
Andrew S Klein, Mrunal S Chapekar |
Valuation of complex license contracts | |
Ralph Villiger, Boris Bogdan |
How can pharmaceutical and biotechnology companies maintain a high profitability? | |
Klaus J Nickisch, Joachim M Greuel, Kerstin M Bode-Greuel |
Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry | |
J Leslie Glick |
Building biotechnology teams: Personality does matter | |
Anne S York, Kim A McCarthy, Todd C Darnold |
Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement | |
Rob Hanes, Damon Borich |
Legal and Regulatory Updates
Legal and Regulatory Update | |
Gerry Kamstra, John Wilkinson |
Book Reviews
Book Review: Genomics & society: Legal, ethical and social dimensions | |
Dominic Clark |
Book Review: Commercialization of innovative technologies: Bringing good ideas to the marketplace | |
Arlen D Meyers |
Book Review: Biotech funding trends: Insights from entrepreneurs and investors | |
J Leslie Glick |